REG - Genflow Biosciences - Highlights and Key Priorities

Genflow BiosciencesAnnouncement

01/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240201:nRSA4088Ba&default-theme=true

RNS Number : 4088B  Genflow Biosciences PLC  01 February 2024

1 February 2024

 

Genflow Biosciences Plc

 

("Genflow" or "the Company")

 

Genflow Biosciences Releases 2023 Year-End Review and Highlights Key
Priorities for 2024

 

The Company (LSE:GNF) (OTCQB:GENFF), an emerging leader in the field of
longevity research developing therapeutics that potentially halt or slow the
ageing process, is pleased to provide a year-end review and summary of its
progress during 2023 and defined strategic priorities for 2024.

 

The Company achieved many significant accomplishments throughout the year
across all aspects of its business. The full year-end review can be viewed on
Genflow's website:
https://genflowbio.com/genflow-biosciences-plc-2023-year-in-review/.

 

Key 2023 Highlights:

 

·    Genflow expanded its intellectual property portfolio with a
provisional patent application for editing the SIRT6 gene, linked to longevity
and age-related diseases.

 

·    Began trading on the OTCQB Venture Market in the US under the ticker
GENFF, aligned to its US-focused strategy.

 

·    Genflow received positive feedback from the Federal Agency for
Medicines and Health Products in Belgium on the design of Phase I/II clinical
trials for its lead drug candidate, GF-1002, in NASH patients.

 

·    Genflow made several key appointments, including Capital Plus
Partners Ltd as Joint Broker in order to access both institutional and
international investment; Harbor Access for investor relations support; and
Prof. Dr. Sven Francque, an expert in nonalcoholic fatty liver disease and
Prof. Dr. Mary E. Rinella, a fatty liver disease specialist to its Scientific
Advisory Board.

 

Strategic Priorities in 2024:

 

·    Genflow awarded 2.89 million Euros in two new grants that will
broaden its research pipeline and expand the size of its therapeutic markets
over the next three years. (Refer to press release:
https://www.globenewswire.com/news-release/2024/01/18/2811445/0/en/Genflow-Biosciences-Partners-with-Revatis-SA-and-EXO-Biologics-in-Groundbreaking-Aging-Research-Fueled-by-Two-Major-Research-Grants.html)

 

·    Genflow to undertake key Investigational New Drug (IND)-enabling
development activities that will help define the pharmacological and
toxicological properties of its lead drug candidate, GF-1002, and its
potential benefits for NASH patients.

 

·    Initial site selection and QMS framework for clinical readiness,
expected by the end of 2025 for the NASH program.

 

·    Commence preliminary discussions with the European Medicines Agency
(EMA) on Mechanism of Action (MoA) data for Orphan Drug Application (ODA) for
our second compound GF-3001, targeting Werner Syndrome.

 

·    Select Contract Development and Manufacturing Organization (CDMO) for
advancing the GMP manufacturing of the NASH clinical lot of lead drug
candidate, GF-1002.

 

·    Develop and implement project management, budgeting and governance
for collaborative partners, in line with clinical and pre-clinal activities
that will enable IND applications.

 

·    Moving key patent applications under the Patent Cooperation Treaty
(PCT) to the national phase, while further expanding our development pipeline
with new products and new indications.

 

Dr. Eric Leire, CEO of Genflow commented: "The milestones we reached in 2023
were numerous, and I commend our team for their exceptional commitment to
execution and delivery. While 2023 was a pivotal year, we're poised for an
even stronger 2024, as we shift focus to scaling development of our lead drug
candidate, GF-1002, and its potential benefits for NASH patients. With the
support of our partners and the backing of new grants, we are poised to make
meaningful advancements in the field of longevity."

 

Contacts

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32-477-495-881      +1 475 477 9401
                      Jonathan.Paterson@Harbor-access.com

 

 Joint Corporate Brokers
 Clear Capital Markets          Capital Plus Partners Ltd
 Bob Roberts, +44 203 869 6080  Dominic Berger, +44 203 821 6167
                                Keith Swann, +44 0203 821 6169
                                Jon Critchley, +44 0203 821 6168

 

 

About Genflow Biosciences

 

Established in 2020, Genflow Biosciences Ltd is a UK-based biotechnology
company, with R&D facilities in Belgium, developing and researching
potential novel therapeutics that halt or slow the ageing process enabling
society to live longer, healthier lives. Genflow Biosciences' lead compound
GF-1002 works through the delivery of a centenarian variant of the SIRT6 gene,
which has yielded promising preclinical results. Genflow Biosciences expects
to commence a clinical trial in 2024 to study the potential benefit of GF-1002
in non-alcoholic steatohepatitis (NASH) for which there are few or no approved
therapies. By treating ageing as a risk factor to disease, Genflow Biosciences
aims to reduce the financial, emotional, and social costs of an ageing
population. For more information: www.genflowbio.com
(http://www.genflowbio.com)

 

DISCLAIMER

The contents of this announcement have been prepared by, and are the sole
responsibility of, the Company.

This announcement may contain forward-looking statements. The forward-looking
statements include, but are not limited to, statements regarding the Company's
or the Directors' expectations, hopes, beliefs, intentions or strategies
regarding the future. In addition, any statement that refers to projections,
forecasts or other characterisations of future events or circumstances,
including any underlying assumptions, is a forward-looking statement. The
words "anticipate", "believe", "continue", "could", "estimate", "expect",
"intend", "may", "might", "plan", "possible", "potential", "predict",
"project", "seek", "should", "would" and similar expressions, or in each case
their negatives, may identify forward-looking statements, but the absence of
these words does not mean that a statement is not forward-looking.

Forward-looking statements include all matters that are not historical facts.
Forward-looking statements are based on the current expectations and
assumptions regarding the Company, the business, the economy and other future
conditions. Because forward-looking statements relate to the future, by their
nature, they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict. Forward-looking statements are
not guarantees of future performance and the Company's actual financial
condition, actual results of operations and financial performance, and the
development of the industries in which it operates or will operate, may differ
materially from those made in or suggested by the forward-looking statements
contained in this announcement. In addition, even if the Company's financial
condition, results of operations and the development of the industries in
which it operates or will operate, are consistent with the forward-looking
statements contained in this announcement, those results or developments may
not be indicative of financial condition, results of operations or
developments in subsequent periods. Important factors that could cause actual
results to differ materially from those in the forward-looking statements
include regional, national or global, political, economic, social, business,
technological, competitive, market and regulatory conditions.

Any forward-looking statement contained in this announcement applies only as
of the date of this announcement and is expressly qualified in its entirety by
these cautionary statements. Factors or events that could cause the Company's
actual plans or results to differ may emerge from time to time, and it is not
possible for the Company to predict all of them. The Company expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained in this announcement to
reflect any change in its expectations or any change in events, conditions or
circumstances on which any forward-looking statement contained in this
announcement is based, unless required to do so by applicable law, the
Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and
Transparency Rules of the FCA or the UK Market Abuse Regulation.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDEALFEDLSLEFA